Avamys 27.5mcg nasal spray to treat runny nose, nasal congestion (30 doses of spray)

Dosage form Box x 27.5mcg
Specifications Fluticasone Furoate
Ingredient Bronchial asthma attacks, bronchial asthma

Ingredient

Thành phần cho 1 liều

Composition information	Content
Fluticasone Furoate	27.5mcg

Uses

indications

Avamys drugs are indicated in the following cases:

Adults and teenagers (12 years or older)

Treatment of symptoms in the nose (runny nose, nose congestion, itchy nose and sneezing) and symptoms in the eye (itchy/burning sensation of the eyes and eyes) of the seasonal allergic rhinitis. Age)

Treat the symptoms of the nose (runny nose, nose congestion, itchy nose and sneezing) of both seasonal allergic rhinitis and allergic rhinitis all year round. Strong inflammation.

Dynamic pharmacokinetics

absorption: Fluticason Furoat has been metabolized quite a lot and is not completely absorbed in the liver and intestinal leads to insignificant systemic concentration. When using 110 micrograms once a day via a nasal spray, the concentration of drugs in plasma is reached below the level of quantitative (less than 10 picograms/ml). The absolute bioavailability of Fluticason Furoat when using 880 micrograms three times daily (total daily dose is 2640 micrograms) is 0.50%.

Distribution: Fluticason Furoat's plasma protein is greater than 99%. Fluticason Furoat is widely distributed with an integral distribution in an average stable state of 608 l.

Metabolic: Fluticason Furoat is quickly eliminated (total plasma clearance is 58.7 l/h) from the whole client week mainly due to the metabolism through the liver into an inactive substance without active 17 beta-carboxylic (GW69301X) by Cytochrom P450 enzyme CYP3A4. The main metabolic line is hydrolysis of S-fluoromethyl carbothioat function to form a metabolic 17 beta-carboxylic acid. In vivo studies do not show evidence of the separation of a part of Furoate molecules to form fluticasone.

Elimination: The excretion mainly after oral medication and venous sugar shows Fluticason Furoat and its metabolites excreted in bile. After using the drug by intravenously, the average disposal time of the drug is 15.1 hours. About 1% of oral medication and 2% of the drug dose used by vein are excreted in the urine.

Before taking Avamys 27.5mcg nasal spray to treat runny nose, nasal congestion (30 doses of spray)

How to use

only use Avamys nasal spray through the spray into the nose. It is recommended that patients use the drug regularly to get adequate treatment. The drug acts early about 8 hours after the starting dose. May need medication for a few days to achieve maximum benefits. It is necessary to explain to the patient that the treatment effect of the drug does not appear immediately.

Dosage

Adults and teenagers (12 years or older)

The recommended starting dose is 2 sprays (27.5 micrograms/spray) on each side x1 times/day (total daily dose is 110 micrograms).

Once the symptoms are fully controlled, the reduction of the dose is 1 spray on each side of the nose x1 times/day (the total daily dose is 55 micrograms) may be effective for maintenance treatment.

Children (from 2 to 11 years old)

The initial starting dose is 1 spray (27.5 micrograms/spray) on each side x 1 time/day (total daily dose is 55 micrograms).

Can use 2 sprays on each side of the nose x1 times/day (total daily dose is 110 micrograms) when the patient does not respond fully with a dose of 1 spray on each side of the nose x1 times/day (the total daily dose is 55 micrograms).

Once the symptoms are fully controlled, the dose should be reduced to 1 spray on each side of the nose x1 times/day (the total daily dose is 55 micrograms).

Other objects

There is no data to recommend the use of Avamys nasal spray in the treatment of seasonal allergic rhinitis or allergic rhinitis year -round in children under 2 years old.

No need to adjust the dose for the elderly, patients with renal failure, patients with liver failure.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.What to do when overdose?

Symptoms and signs

In a useful study, people do not observe the unwanted effect of the whole body when using the doses is 24 times higher than the daily dose recommended for adults through nasal spray for more than 3 days.

Treatment

Excavity overdose may not need any treatment but follow -up.

What to do when you forget 1 dose? However, if the time to relax with the next dose is too short, skip the dose and continue the calendar of the drug. Do not use double dose to compensate for missed dose.

Side Effects

When using Avamys, you may experience unwanted effects (ADR).

Common, ADR> 1/100

Respiratory system: Nosebleeds in adults and adolescents, the rate of nosebleeds when using the drug for a long time (more than 6 weeks) is higher than when using the drug in the short space (no more than 6 weeks); Nasal ulcer.

The respiratory system: nose pain, uncomfortable nose (including burning sensation, nose irritation and nose aches), dry nose.

Rare, 1/10000

Bone muscle system: slow growth in children,

The immune system: Hypersensitivity reactions including anaphylaxis, angioedema, rash and urticaria.

When experiencing side effects of the drug, it is necessary to stop using and notify the doctor or go to the nearest medical facility for timely treatment.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

AVAMYS drug is contraindicated in case of hypersensitivity to any ingredient of the drug.

Be cautious when used

Based on other data on another glucocorticoid metabolized by CYP3A4, the recommended drug is not used in combination with Ritonavir due to the risk of increased fluticason furat.

There has been a report on the body effect when using corticosteroids sprayed through the nasal line, especially when taking high doses for a long time. These effects are much less occur than taking oral corticosteroids and may vary in patients and differently between corticosteroids. Observed the deceleration of growth in children with Fluticason Furoat 110 micrograms/day for 1 year. Therefore, the lowest dose should be maintained enough to control symptoms for children. Like other corticosteroids used by other nose, doctors should pay attention to the possibility of the systemic effect of steroids including eye changes.

Unwanted effects on the nose: In clinical test data, unwanted effects are reported as nosebleeds and nose ulcers. Cases of puncturing the nasal wall when using Fluticason Furoat nasal spray has been reported after the circulation.

Corticosteroids inhaled and in the nose can cause the progression of glaucoma and/or cataract. Therefore, closely monitoring for patients with vision changes or a history of internal hypertension (IncrAeased internal pressure IOP), glaucoma and/or cataract.

Hypersensitivity reactions, including anaphylaxis, angioedema, itching and urticaria may occur after the use of Fluticason Furoat nasal spray. Fluticason Furoat should be stopped if these reactions occur.

Effects on the hypothalamus - pituitary - adrenal glands inhibit adrenal inhibitors and cushing due to drugs. When using nasal steroids at higher doses recommended or in sensitive subjects. However, in a 12 -month research in adults and adolescents, 12 patients with higher intraocular pressure than normal (> 21 mmHg) are treated with Fluticason Furoat nasal spray 110 mcg once a day. Also in that study, 7 patients were found to be cataract during the study without being so when starting the study (of which 6 patients were treated with Fluticason Furoat nasal spray 110 mcg once a day and 1 placebo patient).

When used in accordance with the recommended dose, the systemic effect of corticosteroids such as the condition of the cushing and adrenal inhibitors may occur. If these changes occur, slowly stop using Fluticason Furoat nasal spray similar to oral corticosteroid stopping.

The replacement of body corticosteroids with a local corticosteroid may also occur signs of adrenal insufficiency. In addition, some patients may experience corticosteroids, such as joint pain and/or muscle, fatigue, depression. Previous patients who had long -term treatment with corticosteroids of systemic sugar to use corticosteroid drugs on the spot should be carefully monitored in the condition of acute adrenal insufficiency when responding to stress, in patients with asthma or diseases that require prolonged treatment by systemic corticosteroids, reduction of corticosteroid dosage can cause a serious phase of their symptoms.

The ability to drive and operate machinery

Based on the pharmacological pharmacology of Fluticason Furoat and other steroids used by nasal spray, there is no basis to show that the Avamys nasal spray has the ability to drive and operate machinery.

Pregnancy

After using Avamys nasal spray at the maximum dose recommended for people through the nose spray (110 micrograms per day), the concentration of Fluticason Furoat in plasma cannot be quantified and therefore the risk of toxicity on fertility is expected to be very low.

Lactation period

The excretion of Fluticason Furoat into breast milk has not been studied.

Fluticason Furoat uses unknown nasal sugars on breast milk or not.

The use of Fluticason Furoat in women who are breastfeeding should only be considered when the desired benefits for mothers are higher than the potential risk to the baby.

Drug interaction

Fluticason Furoat is quickly eliminated by initial transformation quite a lot through intermediaries Cytochrom P450 3A4. In a medical interactive study between Fluticason Furoat nasal spray with a strong CYP3A4 inhibitor is Ketoconazole, the number of patients with Fluticason Furoat concentration can be measured in plasma in the group using ketoconazole (6 out of 20 patients) higher than the placebo group (1 of 20 patients). The slight increase of this concentration does not lead to a statistical difference to the serum cortisol levels in 24 hours between the two groups.

Data on enzyme inhibitors and enzyme indications suggest that there is no theoretical basis for predicting the conversion interaction between Ruticason Furoat and the metabolism through the cytochrome P450 intermediate of other compounds at clinically appropriate nasal sprays. Therefore, people do not conduct clinical research to survey drug interactions between Fluticason Furoat and other drugs.

Based on the data of Fluticason Propionat, another glucocorticoid metabolized by CYP3A4, it is not recommended to simultaneously use Fluticason Furoat with a powerful inhibitor CYP3A4, Ritonavir because of the risk of secondary body effect due to increased exposure with Fluticason Furoat. High exposure to corticosteroids increases the likelihood of the whole body side effects, such as Cortisol secretion.

Storage

Storage below 30 ° C.

Do not leave in the refrigerator or freezing.

To be out of reach of children.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.